Ophthalmology

The recent analysis has indicated the implant’s relative success in maintaining treatment for NIU without need for supplementary treatments.

Recent data from the GALE trial align with OAKS and DERBY results, indicating a successful treatment of geographic atrophy.

Goldberg’s post hoc analysis has indicated that AREDS and AREDS2 vitamins do not slow either GA progression to the fovea or overall GA growth.

Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.

UBX1325 exhibited noninferiority to aflibercept in difficult-to-treat diabetic macular edema, while maintaining a favorable safety profile in the ASPIRE study.

This post hoc analysis of the two trials also indicated a greater mean increase in best-corrected visual acuity and greater total loss of subretinal fluid than aflibercept.

Parkinson’s is often diagnosed after symptoms of the disease have already begun to appear; these results may lead to a more preemptive indication of pathogenesis.

Clinical evidence may not reflect the incidence of IOI in real-world applications treating age-related macular degeneration and diabetic macular edema.

Lifitegrast shows rapid and sustained relief for dry eye disease, with high satisfaction among providers and patients, according to recent findings.

A study reveals Johnson & Johnson’s TECNIS Odyssey IOL offers excellent vision for presbyopia, with minimal dysphotopsia bothersomeness reported by patients.

BRIMOCHOL PF offers lasting near vision improvement for presbyopia, demonstrating robust efficacy and safety in a landmark Phase 3 study.

Travoprost intracameral implant significantly reduces intraocular pressure and medication use in patients with glaucoma over three years.

A Phase 1/2 trial shows promising results for corneal edema, highlighting significant visual and quality of life improvements with an innovative cell therapy.

Long-term analysis confirms lifitegrast's safety for dry eye treatment, showing no new safety signals in nearly 800,000 patient treatment years.

Cyclosporine 0.09% significantly improves dry eye symptoms in patients inadequately treated with lower concentrations, enhancing quality of life.

Gene therapy could revolutionize retinal disease treatment, promising consistent dosing, fewer injections, and improved patient outcomes, as highlighted by expert Christina Y. Weng.

Innovative drug delivery platform shows significant vision improvement and IOP reduction in glaucoma patients, promising a new treatment paradigm.

Jeffrey Levenson, MD, discusses the sustained reduction of ocular inflammation and pain post ocular surgery with clobetasol propionate ophthalmic suspension.

Katherine Talcott, MD, discuss the impact of intravitreal injections on intraocular pressure, emphasizing monitoring and patient safety in treatment.

Christina Y. Weng, MD, breaks down emerging gene therapy programs poised to change how retina specialists treat chronic eye disease.

Parent company VivaVision plans to request a type C meeting with the US Food and Drug Administration.

Analysis suggests that OCT is more consistently accurate and sensitive than color imaging and fluorescein angiography, the accepted standards for imaging.

The FDA identified no issues with the safety or efficacy of aflibercept 8 mg in any of its already approved dosing regimens or indications.

Results indicate that FDD should be accounted for when measuring ganglion cell inner plexiform layer (GCIPL) in eyes with glaucoma.

If approved, aflibercept 8 mg would mark the first RVO treatment indicated for up to every 8-week dosing, halving the injection frequency of other anti-VEGF options.